Marc Rovito

Marc Rovito, MD serves as an Assistant Professor in the Department of Medicine with a research focus spanning oncology, epidemiology, and pandemic response systems. His work primarily investigates cancer patient outcomes during global health crises, particularly through large-scale collaborative initiatives.

Research interests center on cancer-pandemic interactions, evidenced by high-impact studies on COVID-19's clinical impact in oncology patients. His fingerprint reveals expertise in melanoma (100%), malignant neoplasms (76%), breast cancer (66%), and overall survival metrics (38%). Key methodologies include phase III clinical trials (OlympiA), multi-institutional cohort studies (CCC19), and systematic framework development for rapid data acquisition.

Publication trends demonstrate leadership in translational oncology with emphasis on therapeutic interventions across diverse cancer types. His 2020-2023 work shows significant citation impact, particularly the Lancet cohort study (1,409 Scopus citations) and OlympiA trial (161 citations), indicating substantial influence in clinical oncology guidelines and policy.

Rovito's collaborative network spans global institutions through the COVID-19 and Cancer Consortium, with research referenced in 3 clinical guideline sources, 31 policy documents, and 145+ news outlets. His work contributes to UN Sustainable Development Goals related to health equity and pandemic resilience.

Current activities involve quality assurance systems for cancer patient data during health emergencies, therapeutic outcome analysis in melanoma/breast cancer, and clinical trial methodology refinement. Research outputs show consistent engagement with high-impact journals including The Lancet, Annals of Oncology, and Cancer Cell.